|
|
 |
| |
PaxilŽ (paroxetine) is an anti-depressant manufactured by GlaxoSmithKline. Recently Public Health Advisories have been issued for PaxilŽ regarding an increased risk of heart birth defects, persistent pulmonary hypertension (PPHN), omphalocele (an abnormality in newborns in which the infant's intestine or other abdominal organs protrude from the navel) or craniosynostosis (connections between sutures-skull bones, prematurely close during the first year of life, which causes an abnormally shaped skull) in children born to mothers exposed to PaxilŽ.
Recently published case-control study has shown that infants born to mothers who took selective serotonin reuptake inhibitors (SSRIs) after the 20th week of pregnancy were 6 times more likely to have persistent pulmonary hypertension (PPHN) than infants born to mothers who did not take antidepressants during pregnancy (see SSRI drug names at the bottom of this sheet). The background risk of a woman giving birth to an infant affected by PPHN in the general population is estimated to be about 1 to 2 infants per 1000 live births. Neonatal PPHN is associated with significant morbidity and mortality.
Parents of children born with birth defects to a mother who has documented use of PaxilŽ during pregnancy should contact an attorney by filling out the form provided under report your case:
Click Here to contact a lawyer |
|
| |
|
|
|
|
 |
Paxil Heart Defects: Paxil, an anti-depressant manufactured by GlaxoSmithKline has recently been linked to a host of birth defects, including heart birth injuries and PPHN and skull abnormallities. Click Here to report your case
> Report
Your Case |
|
|
|
|
